YAP1 and small cell lung carcinoma: In SCLC, YAP1 induced PD-L1 expression and inhibited immune cell activation and function (Fig. 7), which might explain the mechanism underlying the response of the SCLC-Y subtype to immunotherapy and provide a molecular basis for combining YAP1 inhibitor and PD-L1 inhibitor.